Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Obesity01:24

Obesity

1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

279
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
279
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

199
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
199
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

302
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302
Drug Therapy01:28

Drug Therapy

315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
315

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities.

European cardiology·2026
Same author

Tirzepatide and the NHS: are we creating a two-tier obesity treatment system?

The British journal of general practice : the journal of the Royal College of General Practitioners·2025
Same author

Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study).

Metabolites·2025
Same author

A <u>r</u>andomis<u>e</u>d, controlled, double blind <u>s</u>tudy to assess mechan<u>i</u>stic effects of combination therapy of dapag<u>li</u>flozin with <u>e</u>xenatide QW versus dapagliflozin alone i<u>n</u> obese patients with <u>t</u>ype 2 diabetes mellitus (RESILIENT): study protocol.

BMJ open·2021
Same author

Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.

Expert opinion on pharmacotherapy·2021
Same author

Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).

BMJ open·2020

Related Experiment Video

Updated: Feb 18, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K

Combination therapy for obesity.

John Ph Wilding1

  • 1Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.

Journal of Psychopharmacology (Oxford, England)
|November 15, 2017
PubMed
Summary
This summary is machine-generated.

Obesity pharmacotherapy is evolving, with combination therapies offering improved efficacy and safety over monotherapies. Future strategies aim to match bariatric surgery

Keywords:
Obesitybupropionnaltrexonephenterminetopiramate

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.4K

Related Experiment Videos

Last Updated: Feb 18, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.4K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Obesity is a chronic disease with significant health implications.
  • Lifestyle modifications alone are often insufficient for long-term weight management.
  • Bariatric surgery is effective but not widely accessible.

Purpose of the Study:

  • To review the role of pharmacotherapy in obesity management.
  • To explore the potential of combination therapies for optimizing weight loss.
  • To identify emerging combination strategies for obesity treatment.

Main Methods:

  • Review of current literature on obesity pharmacotherapies.
  • Analysis of existing combination therapies (phentermine/topiramate, naltrexone/bupropion).
  • Exploration of potential future combination treatments.

Main Results:

  • Current monotherapies have limited efficacy or side effects.
  • Combination therapies offer enhanced weight management with potentially fewer adverse effects.
  • Promising future combinations include GLP-1 agonists and SGLT2 inhibitors.

Conclusions:

  • Combination pharmacotherapy represents a significant advancement in obesity treatment.
  • Future research should focus on developing and validating novel combination regimens.
  • The goal is to achieve bariatric surgery-level efficacy with medical interventions.